Skip to main content
L

Lionco Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 603669 ISIN · CNE1000022R8 LEI · 300300EU7LBPZ25TZO93 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,201 across all filing types
Latest filing 2025-09-22 Governance Information
Country CN China
Listing Shanghai Stock Exchange 603669

About Lionco Pharmaceutical Group Co.,Ltd.

Lionco Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and sale of chemical drug preparations. The company specializes in a diverse range of therapeutic areas, including anti-infectives, digestive system treatments, cardiovascular health, and respiratory medicine. Its product portfolio primarily consists of high-end generic drugs, featuring formulations such as freeze-dried powder for injection, small-volume injections, and solid oral dosages. Lionco emphasizes technological innovation and quality control to provide clinical solutions for various medical conditions. The group operates multiple manufacturing facilities and maintains a comprehensive distribution network to serve healthcare providers and patients.

Recent filings

Filing Released Lang Actions
独立董事工作细则（2025年9月修订）
Governance Information Classification · 100% confidence The document is titled '独立董事工作细则' which translates to 'Independent Director Work Rules' for Lingkang Pharmaceutical Group Co., Ltd. It details the duties, qualifications, appointment, and operational procedures for independent directors within the company. The content is focused on governance structure, board responsibilities, and internal rules rather than financial performance, audit results, or shareholder meeting materials. There is no indication of financial data, earnings, voting results, or regulatory filings. This document fits the description of Governance Information (CGR), which covers internal rules, board structure, and governance practices.
2025-09-22 Chinese
股东会议事规则（2025年9月修订）
Governance Information Classification · 100% confidence The document is titled '股东会议事规则' which translates to 'Shareholders Meeting Rules' or 'Rules of Procedure for Shareholders Meetings' for Lingkang Pharmaceutical Group Co., Ltd. It details the procedures, rights, and regulations governing the conduct of shareholders meetings, including the calling, notification, voting, and decision-making processes. It references relevant laws such as the Company Law and Securities Law of China, and covers topics like the powers of the shareholders meeting, proposal submission, voting rights, and meeting conduct. There is no indication that this is an announcement of a meeting, a voting result, or a transcript. It is not a financial report or an earnings release. It is a governance document outlining internal rules and procedures related to corporate governance and shareholder meetings. Therefore, the most appropriate classification is Governance Information (CGR). The document length (9634 characters) supports that this is a substantive governance document rather than a brief announcement or notice.
2025-09-22 Chinese
内幕信息知情人登记管理制度（2025年9月修订）
Governance Information Classification · 95% confidence The document is titled '内幕信息知情人登记管理制度' which translates to 'Insider Information Insider Registration Management System' for Lingkang Pharmaceutical Group Co., Ltd. It details the company's internal policies and procedures for managing insider information, including definitions, scope, responsibilities, confidentiality, and record-keeping requirements. It includes regulatory references to Chinese securities laws and stock exchange rules, and outlines the process for insider registration and management. The document is a governance and compliance policy document rather than a financial report, earnings release, or announcement. It does not contain financial statements, earnings data, or voting results. It is not a report publication announcement or a regulatory filing in the narrow sense but a detailed internal governance document related to insider information management. Therefore, the most appropriate classification is Governance Information (CGR).
2025-09-22 Chinese
董事会议事规则（2025年9月修订）
Governance Information Classification · 100% confidence The document is titled '董事会议事规则' which translates to 'Board Meeting Rules' or 'Rules of Procedure for the Board of Directors' of Lingkang Pharmaceutical Group Co., Ltd. It details the composition, powers, meeting procedures, decision-making processes, and responsibilities of the board of directors. It references relevant laws and regulations such as the Company Law, Securities Law, and listing rules. The content is focused on governance structure and internal rules for board operations rather than financial results, audit opinions, or shareholder meeting materials. It is not an announcement or a report of financial results or voting outcomes. Therefore, this document fits the category of Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2025-09-22 Chinese
关于变更注册资本、取消监事会并修订《公司章程》的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from Lingkang Pharmaceutical Group Co., Ltd. regarding changes in registered capital, cancellation of the supervisory board, and amendments to the company's articles of association. It includes details about convertible bonds converted into shares, changes in total share capital, and legal compliance references. The document is a formal announcement of corporate governance and capital structure changes, not a full report or financial statement. It is not a full Annual Report, Interim Report, or Audit Report. It is not a voting result declaration or a proxy statement. The document is best classified as a Regulatory Filing (RNS) because it is a regulatory announcement about corporate changes and capital adjustments without detailed financial statements or comprehensive report content.
2025-09-22 Chinese
第四届董事会第三十六次会议决议公告
Board/Management Information Classification · 100% confidence The document is a formal announcement of resolutions passed at a board meeting of Lingkang Pharmaceutical Group Co., Ltd. It details nominations for the new board, changes in governance structure including the abolition of the supervisory board, amendments to company bylaws, and the scheduling of a shareholders' meeting. The document includes voting results and references to compliance with laws and stock exchange rules. It does not contain financial statements or detailed financial data, nor is it a transcript or presentation. It is clearly a board/management information announcement about changes in the board and governance structure. The document length is short (2193 characters), and it is not an announcement of a report publication but a substantive announcement of board decisions. Therefore, the appropriate classification is Board/Management Information (MANG).
2025-09-22 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.